Related Experiment Video
Updated: Aug 19, 2026
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Published on: November 19, 2019
Correlation of postoperative survival and angiogenic growth factors in pancreatic carcinoma
M R Knoll1, D Rudnitzki, J Sturm
1Department of Endoscopic Surgery, University Hospital Mannheim University of Heidelberg, Theodor-Kutzer-Ufer, D-68135 Mannheim, Germany.
Background/Aims:
VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor) are promoters of angiogenesis. It was the aim of this study to investigate a possible coexpression of both growth factors in tumor samples of pancreatic cancer patients in relation to survival after resection of the tumor.
Methodology:
We investigated the expression of VEGF165 and EGF in tumor specimen from 19 patients that underwent pancreaticoduodenectomy. Growth factor expression was determined using immunohistochemical methods.
Results:
Coexpression of VEGF165 and EGF was observed in tumor samples of 9 (47%) patients. VEGF165 and EGF expression in the same tumor correlates significantly (P < 0.05, Fisher-test). UICC stage III pancreatic carcinoma patients with VEGF165 negative tumor cells had a significantly better outcome after surgery compared to UICC stage III patients with VEGF165-positive tumor cells (median survival time 19 months vs. 9 months respectively; P < 0.05, Wilcoxon-test).
Conclusions:
Antiangiogenic therapy after surgery for pancreatic cancer may be beneficial, especially for UICC III patients.
